Bicycle Therapeutics plc — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Financial statements are unaudited. Bicycle is a clinical-stage biopharmaceutical company developing synthetic peptide medicines; it has no approved products and generates no product-sales revenue.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $5.4 million | $3.0 million | $21.6 million | $11.3 million |
| Research and development expense | $39.9 million | $22.8 million | $111.8 million | $56.9 million |
| General and administrative expense | $16.3 million | $10.0 million | $45.6 million | $38.8 million |
| Loss from operations | $(50.8) million | $(29.8) million | $(135.7) million | $(84.4) million |
| Net loss | $(49.9) million | $(28.3) million | $(131.6) million | $(82.7) million |
| Basic and diluted net loss per share | $(1.26) | $(0.96) | $(3.95) | $(2.79) |
There is no meaningful product gross margin disclosed because revenue is collaboration-based, not product sales. Operating expenses substantially exceeded collaboration revenue. Q3 operating expenses rose $23.4 million year over year, principally reflecting higher clinical and discovery spending, headcount, professional fees and share-based compensation. Nine-month expenses included $24.7 million of share-based compensation.
At September 30, cash and cash equivalents were $572.1 million, versus $339.2 million at December 31, 2022. Current assets were $603.0 million and current liabilities $69.7 million. The accumulated deficit was $462.7 million.
- Cash flows, nine months: $13.3 million used in operating activities, $2.9 million used in investing activities, and $249.6 million provided by financing activities; cash, cash equivalents and restricted cash increased $233.5 million.
- Operating cash use was lower than the prior-year $55.8 million, largely because collaboration upfront payments increased deferred revenue by $74.2 million. This working-capital benefit should not be mistaken for operating profitability.
- Debt: $30.0 million principal outstanding; balance-sheet carrying value was $30.6 million. The facility bears interest at prime plus 4.55%, subject to an 8.05% floor and 9.05% cap; the reported rate was 9.05%. Interest-only payments run through April 1, 2025, with maturity on July 1, 2025. Up to $45.0 million of additional borrowing is available subject to conditions.
Material changes versus the prior comparable period
- Nine-month collaboration revenue nearly doubled, up $10.4 million, mainly from Genentech, Ionis, and new Bayer and Novartis agreements. Genentech revenue included $6.0 million recognized after termination of one program and expiry of its related option right.
- Nine-month R&D expense increased $54.9 million, led by BT8009 clinical development, Bicycle TICA programs, discovery/platform spending and increased staffing.
- Nine-month net loss widened by $48.8 million. Higher interest income partly offset operating losses.
- July’s public offering generated $215.1 million net proceeds; the ATM program generated $34.2 million net proceeds in the first nine months. These issuances increased share count and diluted existing holders.
Outlook, commentary and risks
- Management expects existing cash to fund operating expenses and capital expenditure requirements for at least 12 months from the November 2, 2023 filing date. It expects continuing losses and substantial expense increases as development advances, and states that additional funding will be needed; the runway estimate depends on assumptions and could prove shorter.
- BT8009, BT5528 and BT7480 are in company-sponsored Phase I/II trials; BT1718 is in a Cancer Research UK-sponsored Phase I/IIa trial. BT7455 is in IND-enabling work. Management reported FDA alignment on the design of a Phase II/III registrational trial for BT8009; in October 2023, BT8009 was selected for the FDA’s CMC Development and Readiness Pilot Program. These developments do not assure approval or commercial success.
- Bayer and Novartis each paid a $45 million and $50 million upfront fee, respectively. Much of the related consideration remains deferred: total deferred revenue was $134.8 million at quarter-end, including material-right amounts recognized only upon option exercise or expiry. Future milestones and royalties are contingent, not guaranteed revenue.
- Unusual items included a $2.4 million Q3 tax provision from a revised conclusion on U.S. research-cost capitalization under IRC Section 174, and a $0.3 million lease-termination loss in the nine-month period. AstraZeneca’s final remaining research program was terminated in April 2023.
- Key risks include clinical failure, delays or enrollment challenges, regulatory uncertainty for a novel therapeutic modality, reliance on third-party manufacturers and CROs, dependence on collaborators, further financing needs and potential dilution, debt obligations, foreign-exchange exposure, and evolving tax and regulatory requirements. The company reported no material legal proceedings; disclosure controls were deemed effective.
Important facts for investors to verify
- Whether clinical data, trial enrollment and regulatory milestones—particularly for BT8009—support the expected development path and timing.
- Whether cash burn accelerates as trials expand, and how the stated cash runway changes with updated spending and collaboration receipts.
- The terms, timing and exercise status of collaboration options, and the distinction between deferred upfront payments and contingent milestones or royalties.
- Future dilution from equity issuance and the terms and repayment requirements of Hercules debt.
- The effect of the Section 174 tax treatment and changes to U.K. R&D tax-credit rules on taxes, expense offsets and cash flows.